NeuraLace Doubles Clinical Trial Enrollment And Improves Participant Compliance With Medrio's EDC and ePRO

Committed to producing innovative non-invasive chronic pain therapies, NeuraLace Medical was in trouble when its initial trial design and participant recruitment initiatives led to insufficient enrollment. Based in San Diego, California, the company developed an Axon Therapy technology, which is an FDA 510(k) approved device for treating nerve pain. For its study, NeuraLace Medical hoped to measure secondary endpoints and identify potential changes to participant quality of life through the use of the magnetic pulse treatment.

“Our investigators understand that there is much more to pain than just the pain scale numbers,” said Joe Milkovits, Chief Operating Officer, NeuraLace. “Are participants moving around more? Do they feel better about their situations? Quality of life matters.”

Find out how the company was able to engage patients in new ways compliant with ePRO.